EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC 4.0

Quality of life for pediatric patients with short bowel syndrome‐associated intestinal failure treated with teduglutide

Danielle Wendel iD, Paul W Wales, Samuel Kocoshis, Robert Venick, Beth Carter, Valeria Cohran, Cheney Matthews, Bram P Raphael, Ian Robinson, Susan Hill

Journal of Pediatric Gastroenterology and Nutrition · 2026-07 · 83 (1) · 54-62

DOI: 10.1002/jpn3.70358 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 19.03.2026. Verfasst von Danielle Wendel und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Short Bowel Syndrome, Quality of Life, Intestinal Failure, Peptides. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Clinical trials NCT02949362 and NCT02954458 were funded by Shire Human Genetic Therapies, Inc., a Takeda company, this post hoc analysis study was funded by Takeda Pharmaceuticals U.S.A., Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The complex care needs of pediatric patients with short bowel syndrome‐associated intestinal failure (SBS‐IF) can negatively impact the health‐related quality of life (HRQoL) of patients and their caregivers. We assessed the impact of teduglutide on HRQoL of pediatric patients with SBS‐IF.

Methods

Two long‐term extension (LTE) studies (NCT02949362, NCT02954458) assessed HRQoL over 96 weeks using the Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales and the PedsQL Family Impact Module. Patients included in this analysis received teduglutide in one of three randomized Phase 3 parent studies and the respective LTE study. We assessed changes in HRQoL over time, as well as the impact of attaining enteral autonomy on HRQoL and predictors of change in HRQoL.

Results

In pediatric patients with SBS‐IF receiving teduglutide ( n = 69), the total mean (standard deviation) patient‐reported PedsQL score was 75.0 (16.2). Higher mean number of stools per day at LTE study baseline ( p = 0.03) predicted increased patient‐reported HRQoL. Longer teduglutide exposure ( p = 0.047), increasing length of remnant small intestine ( p = 0.034), and older age ( p = 0.026) predicted higher caregiver‐proxy‐reported HRQoL. Mean PedsQL scores remained stable over 96 weeks regardless of patients achieving enteral autonomy.

Conclusions

HRQoL of pediatric patients with SBS‐IF treated with teduglutide was generally stable over 96 weeks. Predictors of improved HRQoL included higher baseline stool number, longer teduglutide treatment duration, greater length of small intestine, and older age. To better understand these observations, future studies should assess HRQoL before initiation of treatment. Clinical Trial Registration Clinical trials NCT02949362 and NCT02954458.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Short Bowel SyndromeQuality of LifeIntestinal FailurePeptidesGastrointestinal AgentsHumansFemaleChildMaleAdolescentChild, PreschoolTreatment Outcome

Stichwörter der Autor:innen

gastroenterologyglucagon‐like peptide‐2outcomes research/quality

Substanzen

teduglutidePeptidesGastrointestinal Agents

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, Washington, USA.
  • Division of Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA.
  • Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Division of Gastroenterology, Hepatology, and Nutrition, UCLA Mattel Children's Hospital, Los Angeles, California, USA.
  • Children's Hospital Los Angeles and Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Division of Pediatric Gastroenterology, Hepatology and Nutrition, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.

ORCID-Profile: Danielle Wendel

Förderung

  • Clinical trials NCT02949362 and NCT02954458 were funded by Shire Human Genetic Therapies, Inc.
  • a Takeda company
  • this post hoc analysis study was funded by Takeda Pharmaceuticals U.S.A., Inc.
  • Takeda Pharmaceuticals U.S.A., Inc.

Zitieren

APA

Wendel, D., Wales, P. W., Kocoshis, S., Venick, R., Carter, B., Cohran, V., Matthews, C., Raphael, B. P., Robinson, I., & Hill, S. (2026). Quality of life for pediatric patients with short bowel syndrome‐associated intestinal failure treated with teduglutide. Journal of Pediatric Gastroenterology and Nutrition, 83(1), 54-62. https://doi.org/10.1002/jpn3.70358

Vancouver

Wendel D, Wales PW, Kocoshis S, Venick R, Carter B, Cohran V, et al. Quality of life for pediatric patients with short bowel syndrome‐associated intestinal failure treated with teduglutide. Journal of Pediatric Gastroenterology and Nutrition. 2026;83(1):54-62. doi:10.1002/jpn3.70358

BibTeX
@article{Wendel2026,
  author = {Wendel, Danielle and Wales, Paul W and Kocoshis, Samuel and Venick, Robert and Carter, Beth and Cohran, Valeria and Matthews, Cheney and Raphael, Bram P and Robinson, Ian and Hill, Susan},
  title = {Quality of life for pediatric patients with short bowel syndrome‐associated intestinal failure treated with teduglutide},
  journal = {Journal of Pediatric Gastroenterology and Nutrition},
  year = {2026},
  volume = {83},
  number = {1},
  pages = {54--62},
  doi = {10.1002/jpn3.70358}
}
Kostenlos starten →